Edition:
India

Transgene Receives FDA Clearance To Commence Clinical Development In Ovarian Cancer For TG4050


Monday, 13 May 2019 

May 13 (Reuters) - TRANSGENE SA ::TRANSGENE RECEIVES FDA IND CLEARANCE FOR LEAD MYVAC™ INDIVIDUALIZED IMMUNOTHERAPY, TG4050, TO COMMENCE CLINICAL DEVELOPMENT IN OVARIAN CANCER.TRANSGENE RECEIVES FDA IND CLEARANCE FOR LEAD MYVAC™ INDIVIDUALIZED IMMUNOTHERAPY, TG4050, TO COMMENCE CLINICAL DEVELOPMENT IN OVARIAN CANCER.RECEIVED INVESTIGATIONAL NEW DRUG (IND) CLEARANCE FROM FDA TO PROCEED WITH A PHASE 1 CLINICAL TRIAL OF ITS LEAD MYVAC™ CANDIDATE TG4050.PHASE 1 CLINICAL TRIAL WILL EVALUATE SAFETY AND TOLERABILITY OF TG4050 IN PATIENTS WITH OVARIAN, FALLOPIAN OR PERITONEAL SEROUS CELL CARCINOMA.STUDY, SPONSORED BY TRANSGENE, WILL BE CO-FINANCED BY TRANSGENE AND ITS PARTNER NEC.PHASE 1 CLINICAL TRIAL, EXPECTED TO START IN H2 2019.